Cell Signaling Technology Logo - Extra Large
Trial Size Available Flag
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

ST6GAL1 (F6C3D) Rabbit Monoclonal Antibody #74141

Filter:
  • WB

    Product Specifications

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 58
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    ST6GAL1 (F6C3D) Rabbit Monoclonal Antibody recognizes endogenous levels of total ST6GAL1 protein. This antibody detects a 110 kDa protein of unknown identity in some cell lines.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro170 of human ST6GAL1 protein.

    Background

    Beta-galactoside alpha-2,6-sialyltransferase 1 (ST6GAL1, SIAT1) catalyzes the addition of alpha2,6-linked sialic acids onto terminal N-glycans of cell-surface and secreted glycoproteins (1,2). The sialyltransferase is predominantly located within the trans-Golgi network but also exists as a soluble form within the extracellular matrix. It is widely expressed across multiple tissues, with high levels in the liver, ovary, kidney, and lung (3). ST6GAL1 is a critical regulator of cellular survival and development; it protects macrophages from TNFR1-induced apoptosis (4), modulates monocyte-macrophage differentiation (5), preserves stem cell pluripotency (6), and is a necessary mediator for somatic cell reprogramming (7). ST6GAL1 upregulation is a pathological hallmark of several malignancies, most notably pancreatic, prostate, breast, and ovarian cancers (8). The aberrant elevation of alpha-2,6-sialylation driven by ST6GAL1 promotes a highly aggressive phenotype by facilitating cell proliferation, epithelial-mesenchymal transition (EMT), angiogenesis, invasion, metastasis, and therapy resistance (9).

    Alternate Names

    Alpha 2,6-ST 1; B-cell antigen CD75; Beta-galactoside alpha-2,6-sialyltransferase 1; CMP-N-acetylneuraminate beta-galactosamide alpha-2,6-sialyltransferase; CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,6-sialyltransferase 1; MGC48859; Sialyltransferase 1; sialyltransferase 1 (beta-galactoside alpha-2,6-sialyltransferase); SIAT1; ST6 beta-galactosamide alpha-2,6-sialyltranferase 1; ST6 beta-galactoside alpha-2,6-sialyltransferase 1; ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 1; ST6Gal I; ST6GAL1; ST6GalI; ST6N

    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.